Evolution of the Average Target: Celldex Therapeutics, Inc.

Evolution of the Average Target - Celldex Therapeutics, Inc.

Evolution of the Target Price: Celldex Therapeutics, Inc.

Evolution of the Target Price - Celldex Therapeutics, Inc.

Changes in Analyst Recommendations: Celldex Therapeutics, Inc.

fe7a2fdd50f19105a66382da.951wN0Wm2Mt17inoTIOH9CMuMfWoGMVM0pIyXZJKtqI.vs9IBBqLleZYpm2fFeH1lhp9U8bpa5IKhdZ5Av4Q-5ua8D1fDsCTpB-AcA~93700bfa06dcfc80d847415d09b47474
23/07 Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says MT
22/07 Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating MT
11/06 UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating MT
20/04 Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24 MT
24/03 Celldex Therapeutics Shares Rise After Wolfe Research Upgrade MT
23/03 Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44 MT
26/02 Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating MT
07/11 Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study CI
21/10/25 Mizuho Initiates Celldex Therapeutics at Outperform With $48 Price Target MT
13/10/25 Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target MT
10/05/25 UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating MT
28/04/25 Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target MT
20/03/25 Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target MT
07/10/24 Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target MT
30/09/24 Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target MT
27/09/24 Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform MT
26/09/24 Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight After Barzolvolimab Data MT
26/09/24 Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight MT
18/06/24 Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target MT
11/06/24 Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target MT
21/12/23 TD Cowen Initiates Celldex Therapeutics at Outperform Rating MT
11/11/23 Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target MT
07/11/23 HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating MT
22/08/23 Wells Fargo Starts Celldex Therapeutics With Underweight Rating, $21 Price Target MT
22/08/23 Analyst recommendations: Applovin, BAE Systems, Evercore, Jefferies, Target... Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+128.25%
+38.52%
+18.89%
+8.54%
+13.54%
+21.07%
+30.77%
+68.83%
+19.8%
+59.35%
Average +40.76%
Weighted average by Cap. +29.09%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
28.04USD
Average target price
64.00USD
Spread / Average Target
+128.25%
High Price Target
100.00USD
Spread / Highest target
+256.63%
Low Price Target
29.00USD
Spread / Lowest Target
+3.42%

Analyst Consensus Detail

Analyst consensus - Celldex Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Celldex Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Celldex Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CLDX Stock
  4. Consensus Celldex Therapeutics, Inc.